Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Larimar Therapeutics, Inc.NASDAQ: LRMR
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $64K fell 27.3% year over year, behind the +0.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 26.4% from the prior quarter. Over 3 fiscal years it compounded at +3.2% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -27.3% toward the trailing-twelve-month pace of +0.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 350K USD
- Year-over-year change
- +10.1%
- 4-year CAGR
- +1.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 350K | +10.1% |
| FY2024 | 2024-12-31 | 318K | +2.3% |
| FY2023 | 2023-12-31 | 311K | -2.2% |
| FY2022 | 2022-12-31 | 318K | -2.5% |
| FY2021 | 2021-12-31 | 326K | — |
Depreciation & Amortization vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +0.0% is the 6th highest of 11, against a peer median of +1.6%.
- Over three fiscal years its annual growth of +3.2% compares with a peer median of +13.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.36M USD | +53.3% | -27.5% | — | |
| LTM Mar 2026 | $3.44M USD | -15.5% | +19.5% | 89.4% | |
| LTM Mar 2026 | $3.06M USD | +36.2% | +7.2% | — | |
| LTM Mar 2026 | $2.93M USD | -1.6% | -0.7% | 1.4% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $2.12M USD | +4.8% | +22.0% | — |
| LTM Mar 2026 | $1.65M USD | -13.9% | +19.6% | — | |
| LTM Mar 2026 | CHF 1.61M CHF | -27.3% | +2.0% | 43.6% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K USD | +79.6% | +28.8% | — |
| LTM Mar 2026 | $605K USD | +5.0% | +24.6% | — | |
| LTM Mar 2026 | $326K USD | +0.0% | +3.2% | — | |
| LTM Mar 2026 | $106K USD | -33.8% | -39.0% | 294.4% | |
| Peer median (excluding LRMR) | — | +1.6% | +13.3% | 66.5% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.4M | 24.25M | 27.67M | 73.28M | 154.22M |
| Selling, General & Admin | 12.07M | 12.28M | 14.09M | 17.61M | 18.27M |
| Operating Expenses | 50.47M | 36.53M | 41.76M | 90.89M | 172.5M |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | 350K |
| EBITDA | (50.31M) | (35.04M) | (36.64M) | (80.29M) | (165.32M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.47M) | (36.53M) | (41.76M) | (90.89M) | (172.5M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (171K) | 1.17M | 4.81M | 10.29M | 6.82M |
| Income Before Tax | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| EPS (Diluted) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| Weighted Avg Shares | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Weighted Avg Shares (Diluted) | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.